medonline

Immuno-Oncology

In a variety of sections you can read up on presentations (have a look at the abstracts column), watch experts in discussion in the Scientific Knowledge Exchange, catch up on latest developments with our Breakfast Briefs, Webinars and News Feed or test your knowledge with the immuno-oncology Quizzes.

Immuno-Oncology
ESMO 2018 Impressions
The medonline team was present at ESMO 2018 to learn about recent developments in Oncology, and to get to know the opinion of renownend experts of the field of how they think these new data will affect the current treatment standards.
Immuno-Oncology
Highlights on Gastrointestinal Malignancies
Gastrointestinal (GI) malignancies remain a central focus of research and treatment within the oncology community. Colorectal cancer remains the third most common cancer diagnosed in Europe. Experts focuse extensively on new treatments for malignancies across the GI spectrum.
Werbung
Melanoma Research
Highlights in Melanoma Research and Treatment
In the last years there has been great progress in the treatment of advanced melanoma patients and melanoma research has continued exponentially growing.
Immuno-Oncology
Webinar with PD Dr. Dr. med. Ahmad Jalili on Immunotherapy of Melanoma
PD Dr. Dr. med. Ahmad Jalili, Director Dermatology, Bürgenstock Medical Center, held a webinar on Immunotherapie of Melanoma.
Werbung
Lung Cancer
ESMO Webinar with OA Dr. Maximilian Hochmair
OA Dr. Maximilian Hochmair, Otto-Wagner Hospital, Vienna, held a webinar on selected highlights of the treatment of non-small lung cancer (NSCLC) from the ESMO Congress 2017.
Immuno-Oncology
PACIFIC: Quality of Life is maintained in NSCLC patients treated with durvalumab
In the randomised, double-blind phase III trial PACIFIC, durvalumab has shown to improve PFS while upholding quality of life measures in locally advanced, unresectable NSCLC patients after concurrent chemoradiation.
Immuno-Oncology
CheckMate 032: Efficacy of nivolumab is enhanced in SCLC patients with high TMB with or without Ipilimumab
New research showed that among small cell lung cancer (SCLC) patients, the efficacy of using nivolumab with or without (±) ipilimumab was enhanced among those with a high tumor mutation burden (TMB).
Immuno-Oncology
POPLAR: 3-year survival and duration of response data
In the 3-year-survival analysis of the phase II study POPLAR atezolizumab demonstrated superior 2-year and 3-year overall survival (OS) benefit compared with docetaxel in patients with advanced NSCLC.
Immuno-Oncology
Early predictive biomarkers could identify non-responders to PD-1/PD-L1-Inhibitors
Changes in LDH above the upper limit of normal values at cycle 2 and in NLR ≥ 5 at 6 weeks predicts for disease progression at the first tumour response evaluation.
Immuno-Oncology
The role of immunotherapy for patients with rare mutations
The role of immunotherapy for patients with uncommon EGFR mutations, ROS1 and C-MET who express PD-L1 is still unclear.
Immuno-Oncology
Nivolumab more active in lymph nodes
Immunotherapy has differential effects at different organ sites of metastases.
Immuno-Oncology
Peripheral Blood Biomarkers Associated with Clinical Outcome in NSCLC
Low absolute neutrophil count (ANC), high absolute lymphocyte count (ALC), and high absolute eosinophil count (AEC) was associated with a better outcome of nivolumab treatment.
Immuno-Oncology
Interferon-Gamma a more accurate biomarker than PD-L1?
Interferon-Gamma (IFNG) production by T-cells play a critical role in anti-cancer immune responses.
Immuno-Oncology
PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced NSCLC
There is a positive correlation between increasing cutpoints of PD-L1 expression and ORR and 1yr PFS, but little correlation with 1yr OS in treatment naive and pretreated patients.